Hospira 1Q09

1Q Revenues: $859.7 million (-3%)

1Q Earnings: $114.7 million (earnings were $65.4 million in 1Q08)

Comments: Global Specialty Injectables revenue was down 7.5% to $429.7 million, with Europe, Middle East & Africa sales down 26% to $57.6 million and the Americas down 2% to $333.1 million. Other Global Pharma revenues were $169.1 million in the quarter (+4%). Growth in Other Pharma in the Americas segment and overall performance in Medication Management Systems (MMS), were offset by unfavorable foreign exchange and continued pricing pressure in Specialty Injectable Pharmaceuticals (SIP) in the Europe, Middle East and Africa (EMEA) segment.